SCYNEXIS, Inc.

NasdaqGM:SCYX Voorraadrapport

Marktkapitalisatie: US$50.5m

SCYNEXIS Beheer

Beheer criteriumcontroles 2/4

SCYNEXIS' CEO is David Angulo, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $1.21M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $192.17K. The average tenure of the management team and the board of directors is 2.1 years and 9.5 years respectively.

Belangrijke informatie

David Angulo

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris46.5%
Dienstverband CEO1.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn2.1yrs
Gemiddelde ambtstermijn bestuur9.5yrs

Recente managementupdates

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Analyse CEO-vergoeding

Hoe is David Angulo's beloning veranderd ten opzichte van SCYNEXIS's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

US$101m

Dec 31 2023US$1mUS$565k

US$67m

Sep 30 2023n/an/a

US$72m

Jun 30 2023n/an/a

US$44m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$1mUS$482k

-US$63m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$987kUS$461k

-US$33m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$939kUS$447k

-US$55m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$437k

-US$54m

Sep 30 2019n/an/a

-US$37m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$769kUS$424k

-US$12m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$768kUS$412k

-US$25m

Compensatie versus markt: David's total compensation ($USD1.21M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: David's compensation has increased whilst the company is unprofitable.


CEO

David Angulo (59 yo)

1.8yrs

Tenure

US$1,214,710

Compensatie

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Angulo
CEO, President & Director1.8yrsUS$1.21m0.38%
$ 192.2k
Ivor Macleod
Chief Financial Officer2.1yrsUS$626.90k0.028%
$ 14.0k
Scott Sukenick
Chief Legal Officer & Corporate Secretary7yrsUS$936.70k0.21%
$ 106.6k
Daniella Gigante
Vice President of Human Resources & Information Technologyno datageen gegevensgeen gegevens

2.1yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: SCYX's management team is considered experienced (2.1 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
David Angulo
CEO, President & Director1.8yrsUS$1.21m0.38%
$ 192.2k
Armando Anido
Independent Director5.8yrsUS$98.75k0.066%
$ 33.4k
David Hastings
Independent Director9.2yrsUS$104.25k0.061%
$ 30.9k
Ann Hanham
Independent Director15.9yrsUS$105.25k0.062%
$ 31.5k
Guy MacDonald
Independent Chairman of the Board10yrsUS$128.75k0.085%
$ 42.7k
Steven Gilman
Independent Director9.8yrsUS$106.25k0.063%
$ 32.0k
David Denning
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Peter Pappas
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Oliver Cornely
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Barbara Alexander
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Mahmoud Ghannoum
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paul Nyirjesy
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

9.5yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: SCYX's board of directors are considered experienced (9.5 years average tenure).